Structural biology: Corralling a protein-degradation regulator.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Biomolecules · 2021
   Article
2. Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases.Biomolecules · 2019
   Review
3. The prognostic significance of FBXO2 expression in colorectal cancer.International journal of clinical and experimental pathology · 2018
   Article
4. The devil is in the details: comparison between COP9 signalosome (CSN) and the LID of the 26S proteasome.Current genetics · 2016
   Review
5. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.Seminars in cancer biology · 2016
   Review
6. Higher-Order Assembly of BRCC36-KIAA0157 Is Required for DUB Activity and Biological Function.Molecular cell · 2015
   Article
7. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.Sub-cellular biochemistry
   Review

Corrections and comments

• Comment on
  Crystal structure of the human COP9 signalosome.2014

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as